Therapeutic Margin of Budesonide in Patients with Mild to Severe Asthma

Clinical Therapeutics

Volumn 25, Issue SUPPL. C, 2003, Pages

  Skoner, David P ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Asthma; Budesonide; ICS; Therapeutic margin; Tolerability

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; PREDNISONE; TRIAMCINOLONE;

AGE; ASTHMA; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRY POWDER; GROWTH RETARDATION; HUMAN; LONG TERM CARE; POWDER INHALER; REVIEW;

EID: 0242460556     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80306-5     Document Type: Article

References (54)

1. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1997. Publication 97-4051.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 2002. Publication 02-3659.
3. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(Suppl 39):1-34.
4. Lipworth BJ, Wilson AM. Dose response to inhaled corticosteroids: Benefits and risks. Semin Respir Crit Care Med. 1998;19:625-646.
5. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999;159:941-955.
6. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother. 1998;32:220-232.
7. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma [published erratum appears in J Allergy Clin Immunol. 1998;102:511]. J Allergy Clin Immunol. 1998;101:457-463.
8. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr. 1998;132:976-982.
9. Miyamoto T, Takahashi T, Nakajima S, et al, for the Japanese Pulmicort Turbuhaler Study Group. A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Respirology. 2000;5:247-256.
10. Shapiro G, Mendelson L, Kraemer MJ, et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol. 1998;102:789-796.
11. Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics. 1999;103:414-421.
12. Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol. 1999;83:231-239.
13. Boulet LP, Cockcroft DW, Toogood J, et al. Comparative assessment of safety and efficacy of inhaled corticosteroids: Report of a committee of the Canadian Thoracic Society. Eur Respir J. 1998;11:1194-1210.
14. Beasley R, Sterk PJ, Kerstjens HAM, Decramer M. Comparative studies of inhaled corticosteroids in asthma. Eur Respir J. 2001;17:579-580.
15. Kuna P. A randomized, double-blind, double-dummy, parallel-group, multicenter, dose-reduction trial of the minimal effective doses of budesonide and fluticasone dry-powder inhalers in adults with mild to moderate asthma. Clin Ther. 2003;25:2182-2197.
16. Agertoft L, Pedersen S. A randomized, double-blind dose reduction study to compare the minimal effective dose of budesonide Turbuhaler and fluticasone propionate Diskhaler. J Allergy Clin Immunol. 1997;99:773-780.
17. Brambilla C, Godard P, Lacronique J, et al, for the French Budesonide Trial Group. A 3-month comparative dose-reduction study with inhaled beclomethasone dipropionate and budesonide in the management of moderate to severe adult asthma. Drug Invest. 1994;8:49-56.
18. Selroos O, Backman R, Forsén KO, et al. Clinical efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI with volumatic spacer. A 2-year randomized study in 102 asthma patients. Allergy. 1994;49:833-836.
19. Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7:1839-1844.
20. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child. 1993;69:130-133.
21. Dahlström K, Thorsson L, Larsson P, Nikander K. Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Ann Allergy Asthma Immunol. 2003;90:226-232.
22. Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch Dis Child. 1999;80: 241-247.
23. Edsbäcker S, Szefler SJ. Glucocorticoid pharmacokinetics: Principles and clinical applications. In: Schleimer RP, Busse WW, O'Byrne PM, eds. Inhaled Glucocorticoids in Asthma: Mechanisms and Clinical Actions. New York: Marcel Dekker; 1997:381-445.
24. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther. 2003;25(Suppl C):C28-C41.
25. Harrison TW, Wisniewski A, Honour J, Tattersfield AE. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax. 2001;56:186-191.
26. Weiner P, Berar-Yanay N, Davidovich A, Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest. 1999;116:931-934.
27. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study. Lancet. 2000;356:556-561.
28. Boston Consulting Group. The Cost of Adult Asthma in Canada. Princeton, NJ: Communications Media for Education Inc; 1993.
29. Grahnén A, Jansson B, Brundin RM, et al. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Eur J Clin Pharmacol. 1997;52:261-267.
30. Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J. 1996;9:1427-1432.
31. Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of the Turbuhaler on the hypothalamic-pituitary-adrenal axis in asthmatic subjects: A dose-response study. J Allergy Clin Immunol. 1998;101:312-319.
32. Kemp J, for the Pulmonary and Turbuhaler Study Group. Long-term safety and efficacy of Pulmicort (budesonide) Turbuhaler in asthma. In: Program and abstracts of the Annual Meeting of the American Academy of Allergy and Immunology and the American Thoracic Society; July 15-17, 1995; Chicago, Ill. Abstract.
33. Ribeiro LB. A 12 month tolerance study with budesonide in asthmatic children. In: Program and abstracts of the 13th Congress of the European Academy of Allergology and Clinical Immunology; May 6, 1986; Budapest, Hungary.
34. Scott MB, Skoner DP. Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol. 1999;104:200-209.
35. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med. 1998;157(Suppl):S1-S53.
36. Pedersen S. Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med. 2001;164:521-535.
37. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064-1069.
38. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343:1054-1063.
39. Skoner DP, Szefler SJ, Welch M, et al. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol. 2000;105:259-268.
40. Food and Drug Administration, Division of Pulmonary Drug Products. Class Labeling for Intranasal and Orally Inhaled Corticosteroid Containing Drug Products Regarding the Potential for Growth Suppression in Children. November 9, 1998. Talk Paper. Available at: http://www.fda.gov/cder/news/cs-label.htm.
41. Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am J Respir Crit Care Med. 1998;157:178-183.
42. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in premenopausal women [published erratum appears in N Engl J Med. 2002;346:533]. New Engl J Med. 2001;345:941-947.
43. Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol. 2003;111:736-742.
44. Chapman KR. The impact of budesonide and other inhaled corticosteroid therapies in the management of asthma in children and adults. Clin Ther. 2003;25(Suppl C): C2-C14.
45. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). The use of newer asthma and allergy medications during pregnancy. Ann Allergy Asthma Immunol. 2000;84:475-480.
46. Gerdtham UG, Hertzman P, Jönsson B, Boman G. Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978 to 1991. Med Care. 1996;34:1188-1198.
47. Ädelroth E, Rosenhall L, Glennow C. High dose inhaled budesonide in the treatment of severe steroid-dependent asthmatics. A two-year study. Allergy. 1985;40:58-64.
48. Gay AL, Richardson PDI, Howarth NJ. The influence of budesonide (Pulmicort) on patients' lifestyles in the management of asthma. A multicentre trial in general practice. Clin Trials J. 1989;26:175-180.
49. Nankani JN, Northfield M, Beran YM, Richardson PD. Changes in asthmatic patients' symptoms and lifestyles on institution of inhaled budesonide therapy. Curr Med Res Opin. 1990;12:198-206.
50. Campbell LM, Watson DG, Venables TL, et al. Once daily budesonide Turbohaler compared with placebo as initial prophylactic therapy for asthma. Br J Clin Res. 1991;2:111-122.
51. Raymundo A, Hampel F, Dukes E, Spino C. Budesonide 400 μg once daily via Turbuhaler® dry powder inhaler significantly improves asthma-specific quality of life (QOL) in adult patients with nonsteroid-dependent asthma. Am J Respir Crit Care Med. 1999;159:A761. Abstract.
52. Metzger WJ, Hampel FC Jr, Sugar M. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) is effective and safe in adults previously treated with inhaled corticosteroids. J Asthma. 2002;39:65-75.
53. British Thoracic Society, et al. British guidelines on asthma management: 1995 Review and position statement. Thorax. 1997;52(Suppl 1):S1-S21.
54. Committee on Safety of Medicines/Medicines Control Agency. Reminder: Fluticasone propionate (Flixotide): Use of high doses (>500 μg/twice daily). Curr Probl Pharmacovigilance. 2001;27:10.